Depot leuprorelin acetate versus danazol in the treatment of infertile women with symptomatic endometriosis

M. Rotondi, D. Labriola, F. P. Ammaturo, G. Amato, C. Carella, A. Izzo, S. Panariello

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Purpose of investigation: Endometriosis is a common finding in women with infertility, but the mechanism by which it renders a woman infertile remains unclear. The medical treatment of pelvic endometriosis includes hormonal therapy that directly attacks endometriosis lesions or indirectly by inhibiting endometrial proliferation through estrogenic deprivation. The aim of this study was to compare the efficacy and safety of leuprorelin acetate depot and danazol for endometriosis in infertile women. Methods: This randomized trial involved 81 women 19-41 years old with regular menses and known pelvic endometriosis who were recruited from the Fertility Center of the Second University of Naples between 1992 and 1999. Fifty-four women were given 3.75 mg of leuprolide acetate depot every 28 days for 24 weeks and the remaining 27 took 200 mg of danazol three times daily for 24 weeks. Efficacy assessments were based on pre-admission and end-of-treatment laparoscopic scores and subjective symptoms scores at 4-week intervals during and after treatment. Safety was evaluated by adverse events and clinical laboratory tests. Results: In each group, endometriosis growth and symptoms significantly improved during treatment (p <0.001). Significantly fewer patients randomized to leuprorelin acetate (5.5%) withdrew during treatment compared with 18.5% randomized to danazol (p <0.05). After treatment symptoms returned in each group, but severity was less than at admission at all time points (p <0.02). Hypoestrogenic side-effects were more common in those receiving leuprorelin, particularly hot flushes, but anabolic/androgenic side-effects of weight gain and acne were more common in those receiving danazol. Conclusion: Both leuprorelin acetate depot and danazol are effective in the treatment of endometriosis in infertile patients. The hypoestrogenic side-effects of leuprorelin may be better tolerated than the androgenic, anabolic effects of danazol.

Original languageEnglish
Pages (from-to)523-526
Number of pages4
JournalEuropean Journal of Gynaecological Oncology
Volume23
Issue number6
Publication statusPublished - 2002

Fingerprint

Leuprolide
Danazol
Endometriosis
Acetates
Therapeutics
Safety
Anabolic Agents
Menstruation
Acne Vulgaris
Infertility
Weight Gain
Fertility

Keywords

  • Danazol
  • Endometriosis
  • Gonadotropin-releasing hormone analogues
  • Infertility
  • Leuprorelin acetate depot

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

Rotondi, M., Labriola, D., Ammaturo, F. P., Amato, G., Carella, C., Izzo, A., & Panariello, S. (2002). Depot leuprorelin acetate versus danazol in the treatment of infertile women with symptomatic endometriosis. European Journal of Gynaecological Oncology, 23(6), 523-526.

Depot leuprorelin acetate versus danazol in the treatment of infertile women with symptomatic endometriosis. / Rotondi, M.; Labriola, D.; Ammaturo, F. P.; Amato, G.; Carella, C.; Izzo, A.; Panariello, S.

In: European Journal of Gynaecological Oncology, Vol. 23, No. 6, 2002, p. 523-526.

Research output: Contribution to journalArticle

Rotondi, M, Labriola, D, Ammaturo, FP, Amato, G, Carella, C, Izzo, A & Panariello, S 2002, 'Depot leuprorelin acetate versus danazol in the treatment of infertile women with symptomatic endometriosis', European Journal of Gynaecological Oncology, vol. 23, no. 6, pp. 523-526.
Rotondi, M. ; Labriola, D. ; Ammaturo, F. P. ; Amato, G. ; Carella, C. ; Izzo, A. ; Panariello, S. / Depot leuprorelin acetate versus danazol in the treatment of infertile women with symptomatic endometriosis. In: European Journal of Gynaecological Oncology. 2002 ; Vol. 23, No. 6. pp. 523-526.
@article{2b78260eda9b405ab81685890a58d5c0,
title = "Depot leuprorelin acetate versus danazol in the treatment of infertile women with symptomatic endometriosis",
abstract = "Purpose of investigation: Endometriosis is a common finding in women with infertility, but the mechanism by which it renders a woman infertile remains unclear. The medical treatment of pelvic endometriosis includes hormonal therapy that directly attacks endometriosis lesions or indirectly by inhibiting endometrial proliferation through estrogenic deprivation. The aim of this study was to compare the efficacy and safety of leuprorelin acetate depot and danazol for endometriosis in infertile women. Methods: This randomized trial involved 81 women 19-41 years old with regular menses and known pelvic endometriosis who were recruited from the Fertility Center of the Second University of Naples between 1992 and 1999. Fifty-four women were given 3.75 mg of leuprolide acetate depot every 28 days for 24 weeks and the remaining 27 took 200 mg of danazol three times daily for 24 weeks. Efficacy assessments were based on pre-admission and end-of-treatment laparoscopic scores and subjective symptoms scores at 4-week intervals during and after treatment. Safety was evaluated by adverse events and clinical laboratory tests. Results: In each group, endometriosis growth and symptoms significantly improved during treatment (p <0.001). Significantly fewer patients randomized to leuprorelin acetate (5.5{\%}) withdrew during treatment compared with 18.5{\%} randomized to danazol (p <0.05). After treatment symptoms returned in each group, but severity was less than at admission at all time points (p <0.02). Hypoestrogenic side-effects were more common in those receiving leuprorelin, particularly hot flushes, but anabolic/androgenic side-effects of weight gain and acne were more common in those receiving danazol. Conclusion: Both leuprorelin acetate depot and danazol are effective in the treatment of endometriosis in infertile patients. The hypoestrogenic side-effects of leuprorelin may be better tolerated than the androgenic, anabolic effects of danazol.",
keywords = "Danazol, Endometriosis, Gonadotropin-releasing hormone analogues, Infertility, Leuprorelin acetate depot",
author = "M. Rotondi and D. Labriola and Ammaturo, {F. P.} and G. Amato and C. Carella and A. Izzo and S. Panariello",
year = "2002",
language = "English",
volume = "23",
pages = "523--526",
journal = "European Journal of Gynaecological Oncology",
issn = "0392-2936",
publisher = "S.O.G. CANADA Inc.",
number = "6",

}

TY - JOUR

T1 - Depot leuprorelin acetate versus danazol in the treatment of infertile women with symptomatic endometriosis

AU - Rotondi, M.

AU - Labriola, D.

AU - Ammaturo, F. P.

AU - Amato, G.

AU - Carella, C.

AU - Izzo, A.

AU - Panariello, S.

PY - 2002

Y1 - 2002

N2 - Purpose of investigation: Endometriosis is a common finding in women with infertility, but the mechanism by which it renders a woman infertile remains unclear. The medical treatment of pelvic endometriosis includes hormonal therapy that directly attacks endometriosis lesions or indirectly by inhibiting endometrial proliferation through estrogenic deprivation. The aim of this study was to compare the efficacy and safety of leuprorelin acetate depot and danazol for endometriosis in infertile women. Methods: This randomized trial involved 81 women 19-41 years old with regular menses and known pelvic endometriosis who were recruited from the Fertility Center of the Second University of Naples between 1992 and 1999. Fifty-four women were given 3.75 mg of leuprolide acetate depot every 28 days for 24 weeks and the remaining 27 took 200 mg of danazol three times daily for 24 weeks. Efficacy assessments were based on pre-admission and end-of-treatment laparoscopic scores and subjective symptoms scores at 4-week intervals during and after treatment. Safety was evaluated by adverse events and clinical laboratory tests. Results: In each group, endometriosis growth and symptoms significantly improved during treatment (p <0.001). Significantly fewer patients randomized to leuprorelin acetate (5.5%) withdrew during treatment compared with 18.5% randomized to danazol (p <0.05). After treatment symptoms returned in each group, but severity was less than at admission at all time points (p <0.02). Hypoestrogenic side-effects were more common in those receiving leuprorelin, particularly hot flushes, but anabolic/androgenic side-effects of weight gain and acne were more common in those receiving danazol. Conclusion: Both leuprorelin acetate depot and danazol are effective in the treatment of endometriosis in infertile patients. The hypoestrogenic side-effects of leuprorelin may be better tolerated than the androgenic, anabolic effects of danazol.

AB - Purpose of investigation: Endometriosis is a common finding in women with infertility, but the mechanism by which it renders a woman infertile remains unclear. The medical treatment of pelvic endometriosis includes hormonal therapy that directly attacks endometriosis lesions or indirectly by inhibiting endometrial proliferation through estrogenic deprivation. The aim of this study was to compare the efficacy and safety of leuprorelin acetate depot and danazol for endometriosis in infertile women. Methods: This randomized trial involved 81 women 19-41 years old with regular menses and known pelvic endometriosis who were recruited from the Fertility Center of the Second University of Naples between 1992 and 1999. Fifty-four women were given 3.75 mg of leuprolide acetate depot every 28 days for 24 weeks and the remaining 27 took 200 mg of danazol three times daily for 24 weeks. Efficacy assessments were based on pre-admission and end-of-treatment laparoscopic scores and subjective symptoms scores at 4-week intervals during and after treatment. Safety was evaluated by adverse events and clinical laboratory tests. Results: In each group, endometriosis growth and symptoms significantly improved during treatment (p <0.001). Significantly fewer patients randomized to leuprorelin acetate (5.5%) withdrew during treatment compared with 18.5% randomized to danazol (p <0.05). After treatment symptoms returned in each group, but severity was less than at admission at all time points (p <0.02). Hypoestrogenic side-effects were more common in those receiving leuprorelin, particularly hot flushes, but anabolic/androgenic side-effects of weight gain and acne were more common in those receiving danazol. Conclusion: Both leuprorelin acetate depot and danazol are effective in the treatment of endometriosis in infertile patients. The hypoestrogenic side-effects of leuprorelin may be better tolerated than the androgenic, anabolic effects of danazol.

KW - Danazol

KW - Endometriosis

KW - Gonadotropin-releasing hormone analogues

KW - Infertility

KW - Leuprorelin acetate depot

UR - http://www.scopus.com/inward/record.url?scp=0036949988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036949988&partnerID=8YFLogxK

M3 - Article

C2 - 12556096

AN - SCOPUS:0036949988

VL - 23

SP - 523

EP - 526

JO - European Journal of Gynaecological Oncology

JF - European Journal of Gynaecological Oncology

SN - 0392-2936

IS - 6

ER -